Skip to main content

Table 3 Mean of responding and non-responding lesions, where a reduction in TLG of at least 50% was chosen to represent a significant metabolic response

From: Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma

Parameter

Mean value

p value

Significant response

Non-significant response

Baseline TLGa

932 ± 1522

2152 ± 2302

0.101

Baseline SUVmaxb

11.4 ± 3.8

12.3 ± 5.1

0.336

Baseline volume (cc)

182 ± 264

333 ± 346

0.162

Davgc

74 ± 32

61 ± 38

0.299

D70d

42 ± 16

37 ± 31

0.617

V50e

54 ± 26

48 ± 30

0.548

BED

85 ± 44

75 ± 56

0.604

EUD

49 ± 16

39 ± 22

0.146

CoVdosef

0.542 ± 0.198

0.758 ± 0.356

0.030

CoVSUVg

0.274 ± 0.103

0.266 ± 0.069

0.806

  1. aTotal lesion glycolysis
  2. bStandardised uptake value (maximum)
  3. cAverage dose
  4. dMinimum dose to 70% of volume
  5. eVolume receiving at least 50 Gy
  6. fCoefficient of variation of absorbed dose
  7. gCoefficient of variation of SUV
Back to article page